FDA EIR - Smith & Nephew - June 24, 2014

The FDA conducted an inspection of Smith & Nephew's facility in Cordova, TN, from June 23-24, 2014. This site specializes in developing Class I, II, and III orthopedic implants and surgical tools. The inspection focused on the company's management practices, document controls, design processes, and its system for corrective and preventive actions (CAPA), operating under the broader quality system shared by Smith & Nephew facilities in the Memphis area. While the inspection ultimately resulted in a "No Action Indicated" classification, signifying no major regulatory violations, several verbal observations were raised. These included the need to improve the frequency of management reviews, resolve discrepancies in document control for a specific Risk Management Plan, and enhance the clarity of the CAPA procedure. The inspection was conducted under the authority of the Food, Drug, and Cosmetic Act, which governs medical device compliance. Company management acknowledged these observations and committed to addressing them. Although no formal enforcement actions were required, Smith & Nephew was reminded of its responsibility to maintain continuous compliance with FDA regulations. A routine follow-up inspection is planned for July 2016 to ensure sustained adherence to quality system standards.